Barcelona

• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye … Recruiting
  2023-507677-18-00 9 2024-05-17 Chronic Myeloid Leukemia
• Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, th … Recruiting
  2023-509204-15-00 4 2024-05-17 Metastatic colorectal cancer
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 4 2024-05-13 Acute lymphoid leukemia
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga … Recruiting
  2023-504600-28-00 10 2024-05-09 Metastatic Hepatocellular Carcinoma (HCC)
• First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma Recruiting
  2023-507213-97-00 1 2024-05-09 Relapsed/refractory B-cell aggressive lymphoma
• Comparison of PENG block and lumbar plexus block in terms of postoperative analgesia and mobilization for fast track primary hip arthroplast … Recruiting
  2023-507506-14-01 6 2024-05-08 Total Hip Arthroplasty
• Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting
  2024-511397-70-00 4 2024-05-06 metastatic renal cell carcinoma (mRCC)
• The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Recruiting
  2022-500319-38-00 4 2024-05-03 Paroxysmal supraventricular tachycardia (PSVT)
• Basket study for oligo-metastatic breast cancer - ANISE Recruiting
  2023-505039-11-00 4 2024-05-02 breast cancer, HER2-positive, oligometastatic disease
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip … Recruiting
  2023-507305-33-00 7 2024-04-29 Patients with ER+ HER2- advanced breast cancer and patients with high-
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)
• A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome (COMBAT tria … Recruiting
  2023-507073-18-00 4 2024-04-24 Cirrhosis
• A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people … Recruiting
  2022-502576-23-00 1 2024-04-17 Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive
• Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting
  2023-504044-34-00 4 2024-04-17 Untreated Chronic Lymphocytic Leukemia
• A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in pa … Recruiting
  2023-505791-30-01 10 2024-04-17 Diabetic Retinopathy
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting
  2023-504865-21-00 5 2024-04-15 Essential Thrombocythemia patients who have an inadequate response to
• Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted a … Recruiting
  2023-508442-18-00 5 2024-04-14 Patients with an infection of the osteosynthesis material implanted af
• A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting
  2023-504374-38-00 5 2024-04-12 Locally advanced cervical cancer
• A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors Recruiting
  2023-505358-16-00 1 2024-04-11 Advanced Solid Tumors
• VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting
  2023-507293-40-00 6 2024-04-11 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA

Showing 1,321–1,344 of 3,391 trials